Quarterly ResultApr 28, 2026, 05:17 PM
EKSO Q1 Revenue -36.5% to $2.14M; Net Loss $(6.89M); Going Concern Doubt
AI Summary
Ekso Bionics Holdings, Inc. reported a significant decline in revenue and a widened net loss for the first quarter ended March 31, 2026. Revenue decreased by 36.5% year-over-year to $2.14 million, while the net loss increased to $(6.89) million from $(2.89) million in the prior year. The company also disclosed substantial doubt about its ability to continue as a going concern, with current cash expected to fund operations only into early Q3 2026, despite raising $5.27 million from preferred stock and warrant issuance.
Key Highlights
- Substantial doubt about the company's ability to continue as a going concern.
- Q1 2026 revenue decreased 36.5% to $2.14 million from $3.38 million in Q1 2025.
- Q1 2026 net loss widened to $(6.89) million from $(2.89) million in Q1 2025.
- Basic and diluted net loss per share was $(2.04) in Q1 2026, compared to $(1.84) in Q1 2025.
- Cash and restricted cash increased to $3.99 million as of March 31, 2026, from $1.17 million.
- Net cash used in operating activities was $(2.12) million in Q1 2026.
- Raised $5.27 million from Series B Preferred Stock and Private Placement Warrants in Q1 2026.
- Management estimates cash on hand will fund operations into early Q3 2026.